LAVA Therapeutics (NASDAQ:LVTX) Short Interest Update

LAVA Therapeutics (NASDAQ:LVTX) was the recipient of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 21,100 shares, a decrease of 20.1% from the November 15th total of 26,400 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average trading volume of 61,100 shares, the short-interest ratio is currently 0.3 days.

Hedge Funds Weigh In On LAVA Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LVTX. Pathway Financial Advisors LLC lifted its holdings in shares of LAVA Therapeutics by 328.6% during the 2nd quarter. Pathway Financial Advisors LLC now owns 60,000 shares of the company’s stock valued at $108,000 after buying an additional 46,000 shares during the period. XTX Topco Ltd bought a new position in shares of LAVA Therapeutics during the 2nd quarter valued at $55,000. Finally, Virtu Financial LLC bought a new position in shares of LAVA Therapeutics during the 3rd quarter valued at $32,000.

LAVA Therapeutics Trading Down 7.5 %

LVTX stock traded down $0.09 during midday trading on Friday, hitting $1.11. The company’s stock had a trading volume of 157,486 shares, compared to its average volume of 528,124. The company has a market cap of $28.14 million, a PE ratio of -1.08 and a beta of 0.43. LAVA Therapeutics has a 12 month low of $1.08 and a 12 month high of $6.47. The firm’s 50-day moving average is $1.69 and its 200-day moving average is $1.82.

Analyst Ratings Changes

A number of research analysts have weighed in on LVTX shares. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday. JMP Securities reiterated a “market perform” rating and set a $6.00 target price on shares of LAVA Therapeutics in a report on Wednesday. Leerink Partnrs cut LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Finally, Leerink Partners reissued a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a research report on Thursday. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.67.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.